244 related articles for article (PubMed ID: 22752396)
1. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
[TBL] [Abstract][Full Text] [Related]
2. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
4. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
[TBL] [Abstract][Full Text] [Related]
5. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
[TBL] [Abstract][Full Text] [Related]
6. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
[TBL] [Abstract][Full Text] [Related]
7. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
[TBL] [Abstract][Full Text] [Related]
8. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
[TBL] [Abstract][Full Text] [Related]
9. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
[TBL] [Abstract][Full Text] [Related]
10. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
[TBL] [Abstract][Full Text] [Related]
12. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
Biggar P; Ketteler M; Hennemann H; Dömling R
Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
14. Peginesatide in patients with anemia undergoing hemodialysis.
Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
McCullough PA; Barnhart HX; Inrig JK; Reddan D; Sapp S; Patel UD; Singh AK; Szczech LA; Califf RM
Am J Nephrol; 2013; 37(6):549-58. PubMed ID: 23735819
[TBL] [Abstract][Full Text] [Related]
16. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
Kuragano T; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Kitamura K; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura I; Nakanishi T
Kidney Int; 2014 Oct; 86(4):845-54. PubMed ID: 24759150
[TBL] [Abstract][Full Text] [Related]
17. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
Kalim S; Tamez H; Wenger J; Ankers E; Trottier CA; Deferio JJ; Berg AH; Karumanchi SA; Thadhani RI
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1927-34. PubMed ID: 23970130
[TBL] [Abstract][Full Text] [Related]
18. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
[TBL] [Abstract][Full Text] [Related]
19. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
[TBL] [Abstract][Full Text] [Related]
20. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]